The implementation of the ICH E14 guidance has transformed cardiac monitoring in clinical trials. The “Thorough QT/QTc” or Definitive QT trial has become a critical component of EMEA and FDA submissions, creating increased focus on cardiac monitoring and ECG quality throughout drug development. If your next trial requires extensive cardiac monitoring, you should know that MDS Pharma Services offers the expertise to guide you from development through submission. And you can feel confident in your trial results because of our well-established history of producing high-quality ECG data.
Highest Quality Data
Large Phase 1 Capacity
The Heart of Cardiac Safety Monitoring;
R&D Directions, Feb 08 Article
- Joy Olbertz, Ph.D., Pharm. D.
The Thorough QT Study;
European Pharmaceutical Contractor, Spring 08
- Benoit Tyl, M.D.; William S. Wheeler, MD; Joy Olbertz, Ph.D., Pharm.D.
New Phase I clinic in Phoenix, AZ